Company profile
Newave Pharmaceutical Inc
Privately held: no public share price (US entity wholly owned by privately held Lupeng Pharmaceutical; no independent public equity. Parent: Lupeng Pharmaceutical Ltd (private). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.prnewswire.com/news-releases/guangzhou-lupengnewave-pharmaceutical-inc-enrolled-the-first-patient-in-the-global-phase-3-rocket-cll-trial-evaluating-rocbrutinib-lp-168-vs-pirtobrutinib-in-rr-cllsll-302779014.html]) · United States
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Bcl-2 / Bcl-xL | Acute Myeloid Leukemia |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.